4.7 Article

Efficient molecular subtype classification of high-grade serous ovarian cancer

期刊

JOURNAL OF PATHOLOGY
卷 236, 期 3, 页码 272-277

出版社

WILEY
DOI: 10.1002/path.4536

关键词

serous ovarian cancer; molecular subtypes; classification; TaqMan low-density arrays; Nanostring; Fluidigm; Illumina targeted RNA expression

资金

  1. Ovarian Cancer Research Program of the US Department of Defense [W81XWH-12-1-0104]
  2. US Army Medical Research and Materiel Command [DAMD17-01-1-0729]
  3. Cancer Council Victoria
  4. Queensland Cancer Fund
  5. Cancer Council New South Wales
  6. Cancer Council South Australia
  7. Cancer Foundation of Western Australia
  8. Cancer Council Tasmania
  9. National Health and Medical Research Council of Australia [NHMRC 400413, 400281]
  10. Ovarian Cancer Australia (OCA)
  11. Peter MacCallum Cancer Foundation

向作者/读者索取更多资源

High-grade serous carcinomas (HGSCs) account for approximately 70% of all epithelial ovarian cancers diagnosed. Using microarray gene expression profiling, we previously identified four molecular subtypes of HGSC: C1 (mesenchymal), C2 (immunoreactive), C4 (differentiated), and C5 (proliferative), which correlate with patient survival and have distinct biological features. Here, we describe molecular classification of HGSC based on a limited number of genes to allow cost-effective and high-throughput subtype analysis. We determined a minimal signature for accurate classification, including 39 differentially expressed and nine control genes from microarray experiments. Taqman-based (low-density arrays and Fluidigm), fluorescent oligonucleotides (Nanostring), and targeted RNA sequencing (Illumina) assays were then compared for their ability to correctly classify fresh and formalin-fixed, paraffin-embedded samples. All platforms achieved>90% classification accuracy with RNA from fresh frozen samples. The Illumina and Nanostring assays were superior with fixed material. We found that the C1, C2, and C4 molecular subtypes were largely consistent across multiple surgical deposits from individual chemo-naive patients. In contrast, we observed substantial subtype heterogeneity in patients whose primary ovarian sample was classified as C5. The development of an efficient molecular classifier of HGSC should enable further biological characterization of molecular subtypes and the development of targeted clinical trials. Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据